Health Care Equipment

Beyond Air

Beyond Air Reports Phase 1 Mid-Trial Data for UNO Trial

Beyond Air released FY2026 Q3 earnings on February 13 Pre-Market EST, actual revenue USD 2.194 M (forecast USD 2.146 M), actual EPS USD -0.8513 (forecast USD -0.8175)

Beyond Air released FY2026 9 Months Earnings on February 13 Pre-Market EST with actual revenue of USD 5.772 M and EPS of USD -3.634

Beyond Air to Release FY2026 Q3 Earnings on February 13, Pre-Market EST, Forecast Revenue USD 2.146 M, EPS USD -0.8175

Beyond Air CEO to attend Noble and BTIG conferences in February

XTL Biopharmaceutical Acquires 85% of Beyond Air's NeuroNOS Subsidiary

BTIG Analyst Maintains Hold Rating on Beyond Air

Beyond Air released FY2026 Semi-Annual Earnings on November 10 After-Market EST, with actual revenue of USD 3.578 M and EPS of USD -2.7473

Beyond Air released FY2026 Q2 earnings on November 10, 2025, After-Market (EST): Actual Revenue USD 1.818 M (Forecast USD 2.536 M), Actual EPS USD -1.2491 (Forecast USD -0.79)

Beyond Air Inc. Publishes SEC 10-Q Report Showing Improved Performance and Product Progress

Beyond Air to Release FY2026 Q2 Earnings on November 10 After-Market EST, Forecast Revenue USD 2.536 M, EPS USD -0.79

Beyond Air released FY2026 Q1 earnings on August 12 After-Market EST, actual revenue USD 1.76 M (forecast USD 1.748 M), actual EPS USD -1.5336 (forecast USD -1.32)

Beyond Air to Release FY2026 Q1 Earnings on August 12 After-Market (EST), Forecast Revenue USD 1.748M, EPS USD -1.32

Beyond Air Inc. Executes 1 for 20 Reverse Stock Split

Beyond Air Shareholders Approve Reverse Stock Split Proposal

Beyond Air Inc. Reports Narrowed Net Loss

Beyond Air released FY2025 Q4 earnings on June 17 After-Market EST, actual revenue USD 1.152 M (forecast USD 1.388 M), actual EPS USD -1.7857 (forecast USD -2.44)

Beyond Air released FY2025 earnings on June 17 After-Market EST: Actual Revenue USD 3.705 M (Forecast USD 3.922 M), Actual EPS USD -13.7726 (Forecast USD -14.84)

Beyond Air Reports Q4 Earnings Beat Expectations

Beyond Air, Inc. Reports 220% Revenue Growth and Submits New Application

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

GCL Global

Silexion Therapeutics

MetaVia

MicroAlgo

Vida Global

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

Beyond Air, Inc. (XAIR.US) Q2 Fiscal Year 2026 Earnings Conference Call

Beyond Air, Inc. (XAIR.US) Fiscal Year 2025 Fourth Quarter Earnings Conference Call

Beyond Air, Inc. (XAIR.US) Q3 Fiscal Year 2025 Earnings Conference Call

Beyond Air, Inc. (XAIR.US) Q2 Fiscal Year 2025 Earnings Conference Call

XAIR

PLYX

KALV

Short sellers have increased their positions in small-cap healthcare stocks, particularly those under $2 billion market cap, leading to heightened bearish sentiment. Sensei Biotherapeutics tops the list with a short interest of 63.85%, followed by KalVista Pharmaceuticals at 38.35%. Conversely, Beyond Air and Polaryx Therapeutics have minimal short interest at 0.50%. The healthcare sector has underperformed, with the Health Care Select Sector SPDR® Fund declining 6.23% year-to-date, despite the S&P 500's 5.62% rally.

businessinsider

Polaryx Therapeutics

KalVista Pharma

Most and least shorted healthcare stocks with up to $2B market cap in May

Beyond Air rose 14.13%; Abbott rose 1.47%, with a transaction volume of USD 668 million; Intuitive Surgical rose 3.20%, with a transaction volume of USD 414 million; Boston Scientific rose 1.70%, with a transaction volume of USD 303 million; Stryker rose 1.75%, with a market value of USD 131.9 billion

Price Alert

U.S. stock market midday update: Beyond Air up 14.13%, CEO attends meeting to boost confidence, Nasdaq non-compliance risk intensifies!

CDNA

VVOS

EUDA

In Wednesday's after-market session, several health care stocks experienced notable movements. BioAtla (NASDAQ:BCAB) rose by 11.0% to $5.00, while CareDx (NASDAQ:CDNA) increased by 10.52% to $19.42. Other gainers included Beyond Air (NASDAQ:XAIR) up 9.1%, EUDA Health Holdings (NASDAQ:EUDA) up 8.87%, and Actuate Therapeutics (NASDAQ:ACTU) up 8.37%. Conversely, QuidelOrtho (NASDAQ:QDEL) saw a significant drop of 22.8% to $13.50, with NexGel (NASDAQ:NXGL) and Vivos Therapeutics (NASDAQ:VVOS) also declining. Overall, the session highlighted both gains and losses in the health care sector.

benzinga_article

Caredex

Vivos Therapeutics

Euda Health

QuidelOrtho

BioAtla

Actuate Therapeutics

SPDR S&P Biotech

iShares US Medical Devices

Invesco Biotechnology & Genome ETF

SPDR S&P Health Equip

iShares Biotechnology ETF

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Genomics Immunology and Healthcare ETF

SPDR S&P Health

iShares US Healthcare Providers

VG Health

Invesco Nasdaq Biotechnology ETF

American Shared Hosp

Nexgel

Wellgistics Health

Propanc Biopharma

Pasithea Therapeutics

Euda Health - CW22

NEXGEL INC C/WTS 27/12/2026 (TO PUR COM)

PROPANC BIOPHARMA INC

PASITHEA THERAPEUTICS CORP C/WTS 12/08/2026 (TO PUR COM)

12 Health Care Stocks Moving In Wednesday's After-Market Session

Beyond Air has received a notice from Nasdaq regarding noncompliance with the $1.00 bid-price requirement under Listing Rule 5550(a)(2). The company has requested a hearing with the Nasdaq Hearings Panel, scheduled for May 14, 2026, to appeal this determination. Any potential delisting or suspension is on hold until the Panel's decision is made, and there is no guarantee that the Panel will allow continued listing or that compliance will be achieved.

TradingView

Beyond Air receives Nasdaq notice over $1 bid-price; hearing set for May 14, 2026

Beyond Air has received a notice of delisting from Nasdaq due to failing to meet the $1.00 minimum bid price requirement for 30 consecutive business days. The company is not eligible for a compliance period due to a prior reverse split. Beyond Air plans to request a hearing by April 14, 2026, which will pause any delisting actions while the stock continues to trade on Nasdaq.

Beyond Air Received Notice of Delisting

Manna Air Delivery, a prominent player in consumer drone delivery, has disclosed a $50 million funding round to expand its successful operations in the United States and Europe. With this round, the total funding for Manna has reached $110 million. The company boasts one of the most operational consumer drone delivery networks globally, having conducted over 250,000 regulated commercial UAV flights. Notable investors in this round comprise ARK Invest, recognized for supporting firms like OpenAI.

Unusual Whales

Manna Air Delivery Raises $50Million Series B as It Announces Plans to Expand in the United States

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial | XAIR Stock News

StockTitan

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial | XAIR Stock News

Beyond Air(XAIR.US)

Most and least shorted healthcare stocks with up to $2B market cap in May

U.S. stock market midday update: Beyond Air up 14.13%, CEO attends meeting to boost confidence, Nasdaq non-compliance risk intensifies!

12 Health Care Stocks Moving In Wednesday's After-Market Session

Beyond Air receives Nasdaq notice over $1 bid-price; hearing set for May 14, 2026

Beyond Air Received Notice of Delisting

Manna Air Delivery Raises $50Million Series B as It Announces Plans to Expand in the United States

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial | XAIR Stock News